


21 SUPPLEMENTAL FIGURES




23 **Figure S1: Measurement of optical density and SOS response of *E. coli* cells**
24 **embedded in 1% agarose, related to Figure 1.**

25 (A) Optical density of *E. coli* BW25113 cells embedded in 1% agarose exhibits
26 an approximately linear increase with increasing cell density. Shaded
27 region represents one standard deviation above and below mean growth
28 curve ($n = 3$ curves).

29 (B) When *E. coli* BW25113 cells were treated with norfloxacin at three times
30 the minimum inhibitory concentration (MIC), we observed induction of
31 the SOS response in both liquid and agarose. Cells with a *sulA* promoter
32 fusion to GFP were grown in wells of a 96-well plate and fluorescence (λ_{ex}
33 = 485 nm, $\lambda_{\text{em}} = 515$ nm) was quantified using a plate reader. To normalize
34 fluorescence signal to cell density, the optical density was monitored at $\lambda =$
35 595 nm. Shaded regions represent one standard deviation above and
36 below mean growth curves ($n = 3$ biological replicates). A.U., arbitrary
37 units.

38 (C-I) SOS induction was negligible in both liquid and agarose for wild-type
39 cells and six mutants with large-magnitude GRABS scores. Optical density
40 and fluorescence was monitored as in (B).



41

42 **Figure S2: $\Delta mrcA$ and $\Delta mrcB$ cells have distinct mechanical properties, yet**
 43 **their growth rates in liquid and cell morphology in liquid and agarose are**
 44 **similar to each other, related to Figure 2.**


45 A) $\Delta mrcA$ and $\Delta mrcB$ cells do not exhibit substantial changes in cell size
 46 or shape after 8 h of growth embedded in 1% agarose. Blue is a false color
 47 of the phase-contrast image. Green is a false color of the
 48 fluorescence channel from FM4-64 membrane stain. Scale bar: 10 μm .

49 B) $\Delta mrcA$ and $\Delta mrcB$ cells have similar growth rates, with slight growth-
50 rate deficiencies relative to wild-type, in liquid LB. Growth curves
51 were measured by monitoring optical absorbance. Solid lines represent
52 the mean over $n = 3$ curves. Shaded regions represent one standard
53 deviation away from the mean. Maximum growth rates, obtained by
54 fitting to a Gompertz relation: (BW25113, 0.01 min^{-1} ; $\Delta mrcA$, 0.0072
55 min^{-1} ; $\Delta mrcB$, 0.0077 min^{-1}).

56 C) Phase-contrast images of *E. coli* BW25113, $\Delta mrcA$, and $\Delta mrcB$ cells
57 grown in liquid LB. Scale bar: $5 \mu\text{m}$.

58 D) $\Delta mrcA$ and $\Delta mrcB$ cells have similar cellular dimensions as wild-type
59 cells ($n \geq 217$ cells for each strain). Error bars represent one standard
60 deviation from the mean.

61 E) $\Delta mrcA$ cells have a GRABS score indicating that their stiffness is
62 similar to wild-type cells. By definition, wild-type cells have a GRABS
63 score of zero because all measurements are normalized to the wells
64 containing wild-type cells. Error bars are one standard deviation away
65 from the mean ($n = 4$).



67 **Figure S3: Distributions of GRABS scores over time for all Keio strains and**
68 **their correlation to cellular dimensions, related to Figure 2.**


69 (A) Distribution of GRABS scores over time. GRABS scores were calculated as
70 described in the Extended Experimental Procedures, but with the time
71 point of the final OD measurement varied from $t = 3$ h to $t = 14$ h. Curves
72 are shown with variable shifts along the y -axis for visual clarity. The
73 largest range of GRABS scores occurred after ~ 8 h of growth.

74 (B) Distribution of OD values for agarose-embedded growth over time. Kan,
75 kanamycin.

76 (C) Distribution of OD values for liquid growth over time. Kan, kanamycin.

77 (D) GRABS scores are not significantly correlated with average cell width, $n \geq$
78 100 cells for each strain. (Extended Experimental Methods; $p = 0.075$)

79 (E) GRABS scores are not significantly correlated with average cell length, $n \geq$
80 100 cells for each strain. (Extended Experimental Methods; $p = 0.68$)



81

82 **Figure S4: Clean deletions in *E. coli* MG1655 and complementation studies**

83 **validate GRABS measurements of Keio strains, related to Figure 2.**


84 **A) Complementation of four genes that yielded large decreases in GRABS**

85 **score (*mrcB*, *lpoB*, *hfq*, and *hscA*) and two genes that produced**

86 essentially no stiffness change (*mrcA* and *lpoA*) resulted in recovery of
87 mechanical defects when the cells were embedded in 1% agarose.
88 Average growth curves (solid lines) of agarose-embedded *E. coli*
89 BW25113 cells with an empty vector (green) compared to growth
90 curves of Keio BW25113 mutants complemented in *trans* indicate 80-
91 100% recovery after 8 h in $\Delta mrcB$, $\Delta lpoB$, Δhfq , and $\Delta hscA$ and no
92 change in $\Delta mrcA$ and $\Delta lpoA$. Shaded regions represent one standard
93 deviation above and below mean growth curves ($n = 6$).

94 B) We detected no mechanical phenotypes in deletions of genes
95 downstream of *hfq* in the operon containing *hfq*. *tsaE* is not included in
96 the Keio collection and therefore we did not test it.

97 C) The phenotypes of *E. coli* MG1655 mutants embedded in agarose are
98 quantitatively similar to those of the corresponding BW25113 mutants
99 after 8 h. Mean agarose-embedded growth curves of *E. coli* MG1655
100 (green) and selected gene deletions in MG1655 (black) and BW25113
101 (blue). Shaded regions represent one standard deviation above and
102 below the mean ($n = 6$).



103

104 **Figure S5: Responses of *E. coli* mutants to external force, related to Figure 3**

105 **and Figure 4.**

106 (A) Deflection of cells in microfluidic bending device. Greater deflection of


107 $\Delta mrcB$ cells relative to wild-type cells of the same length indicates a

108 decrease in cell stiffness. Circles represent deflection values along the flow
109 direction for individual cells ($n > 200$ cells, two independent experiments).

110 (B) $\Delta recA$ cells exhibit much slower growth in liquid than wild-type BW25113
111 cells. Solid lines are means of $n = 3$ growth curves; shaded regions
112 represent one standard deviation about the mean.

113 (C) $\Delta recA$ cells exhibit similar growth in agarose as wild-type BW25113 cells.
114 Solid lines are means of $n = 3$ growth curves; shaded regions represent one
115 standard deviation about the mean.

116 (D-G) Single-cell, microscopy-based measurements of elongation inhibition
117 agree with GRABS data. Average fractional elongation curves while
118 embedded in 1-4% agarose gels for wild-type and six deletion strains of *E.*
119 *coli* MG1655. The $\Delta mrcB$, $\Delta lpoB$, Δhfq , $\Delta hscA$ mutants consistently display
120 increased inhibition of elongation compared to wild-type, $\Delta mrcA$, and
121 $\Delta lpoA$ cells, as predicted by GRABS scores. L_0 , initial cell length; ΔL , the
122 change in length relative to $t = 0$. Curves are averages over single-cell
123 trajectories and were smoothed over a 5-min window. The number of cells
124 measured decreases over the course of the experiment as some cell
125 trajectories become difficult to track; the initial number of trajectories for a
126 given mutant and agarose concentration ranged from 26-79 across
127 experiments.




128

129 **Figure S6: UPLC analysis of mutants shows no striking differences in**
 130 **peptidoglycan composition between wildtype and several mutants with most**
 131 **negative GRABS scores, related to Figure 3.**

132 (A) Chromatograms of purified cell walls from *E. coli* MG1655, BW25113, and
133 six Keio mutants, including four with large, negative GRABS scores
134 ($\Delta mrcB$, $\Delta hscA$, $\Delta lpoB$, and Δhfq) and two with GRABS scores close to zero
135 ($\Delta mrcA$ and $\Delta lpoA$). Cell walls were purified and digested, and samples
136 were analyzed using UPLC (Extended Experimental Procedures).
137 Chromatograms were normalized to have the same integrated total
138 absorbance and overlaid with baselines staggered for easier comparison.
139 No substantial differences among the chromatograms were evident.

140 (B) Molar fractions of monomers, dimers, trimers, pentapeptides, and
141 anhydro peaks, as well as the glycan strand length computed from total
142 anhydro fraction, were quantified. The low abundance of anhydro species
143 typically leads to greater variability in the calculation of average strand
144 length.



145

146 **Figure S7: Carbonyl cyanide *m*-chlorophenyl hydrazone (CCCP) generally**
 147 **reduces growth rates and the relation of the GRABS score to maximal growth**
 148 **rates in agarose, related to Figure 5 and Figure 2.**

149 (A) Fractional growth-rate of Keio mutants treated with CCCP in liquid.
150 DMSO, dimethyl sulfoxide..

151 (B) Fractional growth-rate of Keio mutants treated with CCCP in agarose is
152 reduced compared to liquid as evidenced by the difference in slopes.
153 DMSO, dimethyl sulfoxide.

154 (C) GRABS scores are correlated with maximal growth rates in agarose.
155 Growth rates were obtained by fitting growth curves for encapsulated
156 cells with a Gompertz relation. The highly significant correlation ($p < 10^{-81}$)
157 indicates that agarose growth rate is a reasonable proxy for GRABS score,
158 potentially simplifying experimental design and analysis, although this
159 simplification is less accurate for some mutants.

160 SUPPLEMENTAL TABLES

161

162 Table S1. Gene Ontology (GO) enrichment of GRABS hits, related to Figure 2

163 and Figure 3.

GO Term	Counts	Definition
GO:0016226	3	iron-sulfur cluster assembly
GO:0009242	2	colanic acid biosynthetic process
GO:0043165	2	Gram-negative-bacterium-type cell outer membrane assembly
GO:0006457	3	protein folding
GO:0043213	2	bacteriocin transport
GO:0006260	3	DNA replication
GO:0015949	2	nucleobase-containing small molecule interconversion
GO:0000162	1	tryptophan biosynthetic process
GO:0006082	1	organic acid metabolic process
GO:0006083	1	acetate metabolic process
GO:0006085	1	acetyl-CoA biosynthetic process
GO:0006105	1	succinate metabolic process
GO:0006220	1	pyrimidine nucleotide metabolic process
GO:0006226	1	dUMP biosynthetic process
GO:0006229	1	dUTP biosynthetic process
GO:0006267	1	pre-replicative complex assembly involved in nuclear cell cycle DNA replication
GO:0006542	1	glutamine biosynthetic process
GO:0006568	1	tryptophan metabolic process
GO:0006749	1	glutathione metabolic process
GO:0007059	1	chromosome segregation
GO:0009220	1	pyrimidine ribonucleotide biosynthetic process
GO:0009399	1	nitrogen fixation
GO:0009443	1	pyridoxal 5'-phosphate salvage
GO:0010608	1	posttranscriptional regulation of gene expression
GO:0015740	1	C4-dicarboxylate transport
GO:0017013	1	protein flavinylation
GO:0019395	1	fatty acid oxidation

GO:0019413	1	acetate biosynthetic process
GO:0019542	1	propionate biosynthetic process
GO:0019676	1	ammonia assimilation cycle
GO:0032298	1	positive regulation of DNA-dependent DNA replication initiation
GO:0033212	1	iron assimilation
GO:0040033	1	negative regulation of translation, ncRNA-mediated
GO:0042351	1	'de novo' GDP-L-fucose biosynthetic process
GO:0042780	1	tRNA 3'-end processing
GO:0042816	1	vitamin B6 metabolic process
GO:0044092	1	negative regulation of molecular function
GO:0045975	1	positive regulation of translation, ncRNA-mediated
GO:0046080	1	dUTP metabolic process
GO:0051050	1	positive regulation of transport
GO:0051085	1	chaperone mediated protein folding requiring cofactor
GO:0051259	1	protein oligomerization
GO:0060274	1	maintenance of stationary phase
GO:0071932	1	replication fork reversal
GO:0009073	2	aromatic amino acid family biosynthetic process
GO:0009252	2	peptidoglycan biosynthetic process
GO:0000271	1	polysaccharide biosynthetic process
GO:0000725	1	recombinational repair
GO:0006259	1	DNA metabolic process
GO:0006269	1	DNA replication, synthesis of RNA primer
GO:0008156	1	negative regulation of DNA replication
GO:0015684	1	ferrous iron transport
GO:0015920	1	lipopolysaccharide transport
GO:0019740	1	nitrogen utilization
GO:0032297	1	negative regulation of DNA-dependent DNA replication initiation
GO:0044237	1	cellular metabolic process
GO:0050821	1	protein stabilization
GO:0051205	1	protein insertion into membrane
GO:0070417	1	cellular response to cold
GO:0097171	1	ADP-L-glycero-beta-D-manno-heptose biosynthetic process
GO:0008360	2	regulation of cell shape

GO:0042710	2	biofilm formation
GO:0015031	2	protein transport
GO:0001123	1	transcription initiation from bacterial-type RNA polymerase promoter
GO:0006261	1	DNA-dependent DNA replication
GO:0006807	1	nitrogen compound metabolic process
GO:0009117	1	nucleotide metabolic process
GO:0017038	1	protein import
GO:0044781	1	bacterial-type flagellum organization
GO:0071973	2	bacterial-type flagellum-dependent cell motility
GO:0006352	1	DNA-templated transcription, initiation
GO:0008615	1	pyridoxine biosynthetic process
GO:0006631	1	fatty acid metabolic process
GO:0010468	1	regulation of gene expression
GO:0006396	1	RNA processing
GO:0006928	1	movement of cell or subcellular component
GO:0045454	1	cell redox homeostasis
GO:0009423	1	chorismate biosynthetic process
GO:0006629	1	lipid metabolic process
GO:0009244	1	lipopolysaccharide core region biosynthetic process
GO:0008033	1	tRNA processing
GO:0006508	1	proteolysis
GO:0006310	1	DNA recombination
GO:0006412	1	translation
GO:0009408	1	response to heat
GO:0008652	2	cellular amino acid biosynthetic process
GO:0046677	1	response to antibiotic
GO:0016310	2	phosphorylation
GO:0006281	1	DNA repair
GO:0009103	1	lipopolysaccharide biosynthetic process
GO:0006974	3	cellular response to DNA damage stimulus
GO:0005975	1	carbohydrate metabolic process
GO:0008152	3	metabolic process
GO:0055114	4	oxidation-reduction process
GO:0006355	2	regulation of transcription, DNA-templated
GO:0006810	4	transport
GO:0006351	1	transcription, DNA-templated

165 **Table S2. Clusters of Orthologous Groups (COGs) for GRABS hits, related to**

166 **Figure 2 and Figure 3.**

COG code	Counts	Definition
A	1	RNA processing and modification
C	8	Energy production and conversion
E	4	Amino acid transport and metabolism
F	2	Nucleotide transport and metabolism
G	1	Carbohydrate transport and metabolism
H	1	Coenzyme transport and metabolism
J	1	Translation, ribosomal structure, and biogenesis
K	2	Transcription
L	6	Replication, recombination, and repair
M	9	Cell wall, membrane, and envelope biogenesis
N	3	Cell motility
O	3	Posttranslational modification and metabolism
P	1	Inorganic ion transport and metabolism
R	1	General function prediction only
S	3	Function unknown
T	3	Signal transduction mechanisms
U	3	Intracellular trafficking, secretion, and vesicular transport
V	1	Cytoskeleton

167

168 **Table S3: Chemical-genomics conditions with the largest-magnitude positive**

169 **Pearson correlation coefficients with stiffness scores. Related to Figure 5.**

170 GRABS scores were correlated with S-scores from the chemical genomics dataset

171 in (Nichols et al., 2011). SDS, sodium dodecyl sulfate.

Condition	Correlation coefficient
Chlorpromazine, 12.0 µg/mL	0.092
Calcofluor	0.079
Chlorpromazine, 3.0 µg/mL	0.079
Ceftazidime, 0.05 µg/mL	0.078
Cefsulodin, 12.0 µg/mL	0.076
SDS, 3.0%	0.075
Cefsulodin, 6.0 µg/mL	0.075
Cefoxitin, 1.0 µg/mL	0.07
Chlorpromazine, 6.0 µg/mL	0.07
Trimethoprim, 0.4 µg/mL	0.068
Dibucaine, 0.8 µg/mL	0.068
Cefaclor, 2.0 µg/mL	0.068
Nigericin, 0.1 µg/mL	0.065
Ampicillin, 8.0 µg/mL	0.065
SDS, 2.0%	0.064
Doxorubicin, 1.0 µg/mL	0.063
Bacitracin, 300 µg/mL	0.063
Ultraviolet light, 18 s	0.061
Cefoxitin, 0.75 µg/mL	0.059
pH 4	0.059

172

173 **Table S4: Chemical-genomics conditions with the largest-magnitude negative**

174 **Pearson correlation coefficients with stiffness scores. Related to Figure 5.**

175 GRABS scores were correlated with S-scores from the chemical genomics dataset

176 in (Nichols et al., 2011). MMS, methyl methanesulfonate; CCCP, carbonyl

177 cyanide *m*-chlorophenyl hydrazone.

Condition	Correlation coefficient
Amoxicillin, 0.5 µg/mL	-0.081
Amoxicillin, 0.25 µg/mL	-0.069
Thiolactomycin, 5.0 µg/mL	-0.062
MMS, 0.05%	-0.060
Tetracycline, 1.0 µg/mL	-0.057
Gentamycin, 0.1 µg/mL	-0.056
Tetracycline, 0.75 µg/mL	-0.056
Thiolactomycin, 1.0 µg/mL	-0.053
CCCP, 0.5 µg/mL	-0.053
CHIR-090, 0.02 µg/mL	-0.053
Nitrofurantoin, 0.5 µg/mL	-0.052
Oxacillin, 5.0 µg/mL	-0.051
Theophylline, 100.0 µg/mL	-0.051
Oxacillin, 0.5 µg/mL	-0.050
High nickel, 0.1 µg/mL	-0.050
Norfloxacin, 0.01 µg/mL	-0.049
Nitrofurantoin, 1.0 µg/mL	-0.048
CCCP, 2.0 µg/mL	-0.046
CCCP, 0.1 µg/mL	-0.046
High nickel, 1.0 µg/mL	-0.046

178

179 **Table S5: Liquid growth-curve data for Keio strains in the absence of**
180 **kanamycin. Related to Figure 2.** Optical density ($\lambda = 595$ nm) was measured as a
181 function of time. Growth data are included as a separate text file.

Table S6: Strains and plasmids used in this study. Related to Figures 1–5.

Strain	Description	Reference/source
MG1655	<i>E. coli</i> K-12 wildtype	CGSC #6300
BW25113	<i>E. coli</i> (Keio collection parent)	(Baba <i>et al.</i> , 2006a)
Keio collection	Single deletion mutants (numbered JW####)	(Baba <i>et al.</i> , 2006a)
DH5 α	F- <i>endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG</i> Φ 80 <i>dlacZ</i> Δ M15 Δ (<i>lacZYA-argF</i>)U169, <i>hsdR17</i> (rK-mK+)	Invitrogen
DH5 α (λ pir)	F- <i>endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG</i> Φ 80 <i>dlacZ</i> Δ M15 Δ (<i>lacZYA-argF</i>)U169, <i>hsdR17</i> (rK-mK+) λ ::pir	Invitrogen
MFDpir	MG1655, RP4-2-Tc::[Δ Mu1:: <i>aac</i> (3)IV- <i>aphA</i> Δ <i>nic35</i> Δ Mu2:: <i>zeo</i>] Δ <i>dapA</i> ::(<i>erm</i> -pir) Δ <i>recA</i>	(Ferrieres <i>et al.</i> , 2010)
HTC1	MG1655 Δ <i>mrcB</i>	This study
HTC2	MG1655 Δ <i>lpoB</i>	This study
HTC3	MG1655 Δ <i>mrcA</i>	This study
HTC4	MG1655 Δ <i>lpoA</i>	This study
HTC5	MG1655 Δ <i>hscA</i>	This study
HTC6	MG1655 Δ <i>hfq</i>	This study
BW25113-E1	BW25113 pBAD33 <i>c280</i>	This study
JW3359-E1	BW25113 <i>mrcA</i> : kan pBAD33 <i>c280</i>	This study
JW3116-E1	BW25113 <i>lpoA</i> : kan pBAD33 <i>c280</i>	This study
JW5157-E1	BW25113 <i>lpoB</i> : kan pBAD33 <i>c280</i>	This study
JW2510-E1	BW25113 <i>hscA</i> : kan pBAD33 <i>c280</i>	This study
JW4130-E1	BW25113 <i>hfq</i> : kan pBAD33 <i>c280</i>	This study
JW3359-C	BW25113 <i>mrcA</i> : kan pBAD33 <i>c280</i> - <i>mrcA</i>	This study
JW3116-C	BW25113 <i>lpoA</i> : kan pBAD33 <i>c280</i> - <i>lpoA</i>	This study
JW5157-C	BW25113 <i>lpoB</i> : kan pBAD33 <i>c280</i> - <i>lpoB</i>	This study
JW2510-C	BW25113 <i>hscA</i> : kan pBAD33 <i>c280</i> -	This study

	<i>hscA</i>	
JW4130-C	BW25113 <i>hfq</i> : kan pBAD33c280- <i>hfq</i>	This study
BW25113-E2	BW25113 pAM238	This study
JW0145-E2	BW25113 <i>mrcB</i> : kan pAM238	This study
JW5157-E2	BW25113 <i>lpoB</i> : kan pAM238	This study
JW1045-C	JW0145 psK12	This study
HTC7	JW0145 psK12-R190D	This study
HTC8	JW0145 psK12-D163A/E166A	This study
HTC9	JW0145 psK12-E233Q (*GT)	This study
HTC10	JW0145 psK12-S510A (*TP)	This study
HTC11	JW0145 psK12-D163A/E166A/E187A/ N188A/R190A/Q191A (6UB2H)	This study
HTC12	JW0145 psK12-(*TP/*GT)	This study
HTC13	JW0145 psK12-(*6UB2H/*TP)	This study
HTC14	JW0145 psK12-(*6UB2H/*GT)	This study
HTC15	JW0145 psK12-(*6UB2H/*TP/*GT)	This study
BW25113-sulA	BW25113 pDB192	This study
JW3359-sulA	BW25113 <i>mrcA</i> : kan pDB192	This study
JW3116-sulA	BW25113 <i>lpoA</i> : kan pDB192	This study
JW1045-sulA	BW25113 <i>mrcB</i> : kan pDB192	This study
JW5157-sulA	BW25113 <i>lpoB</i> : kan pDB192	This study
JW2510-sulA	BW25113 <i>hscA</i> : kan pDB192	This study
JW4130-sulA	BW25113 <i>hfq</i> : kan pDB192	This study
JW4216-sulA	BW25113 <i>holC</i> : kan pDB192	This study
JW2512-sulA	BW25113 <i>iscA</i> : kan pDB192	This study
JW2050-sulA	BW25113 <i>dcd</i> : kan pDB192	This study
JW1075-sulA	BW25113 <i>rpmF</i> : kan pDB192	This study
JW1065-sulA	BW25113 <i>flgG</i> : kan pDB192	This study
JW0891-sulA	BW25113 <i>aroA</i> : kan pDB192	This study
JW2669-sulA	BW25113 <i>recA</i> : kan pDB192	This study
BW25113-E3	BW25113 PUA66	This study
JW1045-E3	BW25113 <i>mrcB</i> : frt pUA66	This study
JW5157-E3	BW25113 <i>lpoB</i> : frt pUA66	This study
JW2510-E3	BW25113 <i>hscA</i> : frt pUA66	This study
JW4130-E3	BW25113 <i>hfq</i> : frt pUA66	This study

JW2512-E3	BW25113 <i>iscA</i> : frt pUA66	This study
JW2669-E3	BW25113 <i>recA</i> : frt pUA66	This study
BW25113- <i>sulA</i> -R	BW25113 PUA66- <i>sulA</i> -GFP	This study
JW1045- <i>sulA</i> -R	BW25113 <i>mrcB</i> : frt pUA66- <i>sulA</i> -GFP	This study
JW5157- <i>sulA</i> -R	BW25113 <i>lpoB</i> : frt pUA66- <i>sulA</i> -GFP	This study
JW2510- <i>sulA</i> -R	BW25113 <i>hscA</i> : frt pUA66- <i>sulA</i> -GFP	This study
JW4130- <i>sulA</i> -R	BW25113 <i>hfq</i> : frt pUA66- <i>sulA</i> -GFP	This study
JW2512- <i>sulA</i> -R	BW25113 <i>iscA</i> : frt pUA66- <i>sulA</i> -GFP	This study
JW2669- <i>sulA</i> -R	BW25113 <i>recA</i> : frt pUA66- <i>sulA</i> -GFP	This study
Plasmid	Description	Reference/source
pDS132	R6K ori, <i>sacB</i> , MCS, <i>cat</i> , CmR	(Phillipe <i>et al.</i> , 2004)
pBAD33 c280	pACYC ori, pBAD promoter, MCS, <i>cat</i> , CmR	(Lee <i>et al.</i> , 2007)
pAM238	pSC101 ori, pLac, SpecR	(Gonzalez <i>et al.</i> , 2010)
pSK12	pAM238- <i>mrcB</i>	(Ranjit and Young, 2013)
pDB195	<i>sulA</i> , pLac, AmpR, CarbR	(Amir <i>et al.</i> , 2014)
pUA66	<i>gfpmut2</i> , KanR	GE Dharmacon
pUA66- <i>sulA</i> -GFP	<i>sulA</i> promoter, <i>sulA</i> - <i>gfpmut2</i>	GE Dharmacon

184 **Table S7. Primers used in this study (5' to 3'). Related to Figure 4.**

Primer (pBAD33 c280)	Sequence
mrcA_C-Fwd	CATGTCTAGATTACGCCAGACGCGGGTTAA
mrcA_C-Rev	CATGTCTAGAGTGAAGTTCGTAAAGTATTTTT
lpoA_C-Fwd	CATGTCTAGAATGGTACCCTCAACATTTTCTCG
lpoA_C-Rev	CATGTCTAGATTAAGTACGCGGGACTACCTGA
lpoB_C-Fwd	CATGTCTAGAATGACAAAAATGAGTCGCTAC GC
lpoB_C-Rev	CATGTCTAGATTATTGCTGCGAAACGGCACCT
hscA_C-Fwd	CATGTCTAGAATGGCCTTATTACAAATTAGTG AACCT
hscA_C-Rev	CATGTCTAGATTAAACCTCGTCCACGGAATG
hfg_C-Fwd	CATGTCTAGAATGGCTAAGGGGCAATCTTTAC A
hfg_C-Rev	CATGTCTAGATTATTCGGTTTCTTCGCTGTCCT
Primer (pSK12)	Sequence
mrcB_R190D_Fwd	CGTCAATATGGAGAACAACGATCAGTTCGGTT TCTTCCG
mrcB_R190D_Rev	CGGAAGAAACCGAACTGATCGTTGTTCTCCAT ATTGACG
mrcB_D163A/E166A_Fwd	CCGTTTGATTTCCCGGCCAGTAAAGCAGGACA GGTGCGCGCG
mrcB_D163A/E166A_Rev	CGCGCGCACCTGTCCTGCTTTACTGGCCGGGA AATCAAACGG
mrcB_R190A/Q191A_Fwd	CGTCAATATGGCGGCCAACGCTGCGTTCGGTT TCTTCCG
mrcB_R190A/Q191A_Rev	CGGAAGAAACCGAACGCAGCGTTGGCCGCCA TATTGACG
mrcB_E187A/N188A_Fwd	CGTCAATATGGCGGCCAACGTCAGTTCGGTT TCTTCCG
mrcB_E187A/N188A_Rev	CGGAAGAAACCGAACTGACGGTTGGCCGCCA TATTGACG
mrcB_S510A_Fwd	GCGTCGTTTCGATTGGTGCCCTTGCAAAACCAG CG
mrcB_S510A_Rev	CGCTGGTTTTGCAAGGGCACCAATCGAACGAC GC
mrcB_E233Q_Fwd	GGATACTTTGCTGGCGACACAAGACCGTCATT TTTACG

mrcB_E233Q_Rev	CGTAAAAATGACGGTCTTGTGTCGCCAGCAAA GTATCC
Primer (pDS132)	Sequence
lpoA_Del_N_term_Fwd	GCATGCAGCGCATCACGGCGGCCT
lpoA_Del_N_term_Rev	TGGTACTCTAGCCATAATGTATCCAGTGATAT TTTTTTTACGCAATGCTCAATATTAATCGGC
lpoA_Del_C_term_Fwd	ATCACTGGATACATTATGGCTACAGTACCAAC AAG
lpoA_Del_C_term_Rev	ATTGAGCAGAGACTGAAC
lpoB_Del_N_term_Fwd	TTGCCGAAGATGGCTATC
lpoB_Del_N_term_Rev	GCTGCGAAACGGCACCAAGATTCACCCCTTAC AAATATAG
lpoB_Del_C_term_Fwd	AAGGGGTGAATCTTGGTGCCGTTTCGCAGCAA T
lpoB_Del_C_term_Rev	CTGACGCGCTATGCACTAAATTTC
mrcA_Del_N_term_Fwd	AGTAAGCAGCGTTGCCAG
mrcA_Del_N_term_Rev	GAAGCGCCT TTTAAATGGAAATTTCCATTTAGTTTCATTG
mrcA_Del_C_term_Fwd	AATGGGAAATTTCCATTA AAAAGGCGCTTCGG C
mrcA_Del_C_term_Rev	ATCCTGATCCGCGAATAC
mrcB_Del_N_term_Fwd	AAATCACTCGACATTTATCAGG
mrcB_Del_N_term_Rev	TTTCACGCTTAGATGGCTTTTTCTCCGCAATAT TC
mrcB_Del_C_term_Fwd	TTGCGGAGAAAAGCCATCTAAGCGTGAAAT ACCG
mrcB_Del_C_term_Rev	TCAGGTGGTCATAGGTGTTG
hscA_Del_N_term_Fwd	ATGGATTACTTCACCCTC
hscA_Del_N_term_Rev	ACAATCTTTGGCATAGTTTAGCTTCCAGAAAT TAAAAATC
hscA_Del_C_term_Fwd	TTCTGGAAGCTAAACTATGCCAAAGATTGTTA TTTTGCCTCATCAGG
hscA_Del_C_term_Rev	GCCAACGCATCTGCGGCG
hfq_Del_N_term_Fwd	CTTCAGGAGGTAGATCCG
hfq_Del_N_term_Rev	AAACAGCCCGAAACCTCTCTTTTCCTTATAT GCTTATTTG
hfq_Del_C_term_Fwd	TAAGGAAAAGAGAGAGGTTTCGGGCTGTTTTT TTAC
hfq_Del_C_term_Rev	CATGCGTACGCCTTTCTGTCTTTCAAGGTG

186 EXTENDED EXPERIMENTAL PROCEDURES

187

188 **Strain and plasmid construction**

189 Table S6 lists the strains and plasmids used in this study for cloning. Primers are
190 described in Table S7. Screening was performed using the Keio collection of non-
191 essential single-gene deletion mutants (Baba et al., 2006). We used allele
192 exchange to individually delete genes in frame in *E. coli* MG1655 without leaving
193 a scar on the chromosome after excision (Philippe et al., 2004).

194

195 **Growth of bacterial cultures for screening**

196 Individual 2-mL cultures were inoculated from a freezer stock and grown
197 overnight in lysogeny broth (LB) at 37 °C with shaking until saturation (~16 h).
198 For this initial overnight culture, Keio mutants were grown in the presence of 30
199 µg/mL kanamycin for selection of the Keio mutant. Strains containing plasmid
200 pBAD33 c280 or plasmid pAM238/pSK12 were grown overnight in 30 µg/mL
201 chloramphenicol or 30 µg/mL spectinomycin, respectively.

202

203 **Preparation of GRABS 96-well plates**

204 The absorbance values ($\lambda = 600$ nm) of 1:10 dilutions in LB of saturated overnight
205 cultures of 48 strains grown in tubes were determined using a spectrophotometer

206 (Amersham Biosciences, Buckinghamshire, UK). Cells were spun down at 800 x g
207 for 10 min, the supernatants were removed, and the pellets were resuspended in
208 1 mL LB to a final density of 0.32 × optical density (OD). To prepare for agarose
209 encapsulation, 48 microstirrers (V&P Scientific, San Diego, CA, USA) were
210 sterilized with 70% ethanol and placed into individual wells in columns 1-6 of a
211 96-well microplate (Thermo Scientific Nunc, Waltham, MA, USA). The
212 microplate was covered with a lid and sterilized with ultraviolet light for 20 min.
213 After sterilization, the microplate was placed onto our custom magnetic surface
214 composed of two magnets (BZ0Z02-N52; KJ Magnetics, Pipersville, PA, USA)
215 mounted in plastic casing, and a new sterile microplate was inverted on top. The
216 two plates were turned over and placed onto the magnetic surface to draw the
217 microstirrers into the new sterile plate. Finally, a sterile lid was placed onto the
218 new microplate, which was transferred to a 50 °C hotplate to warm the plate and
219 magnets for at least 20 min prior to the addition of agarose. This warming step
220 ensured that the agarose remained in solution after being added to the plate.

221

222 Agarose was prepared as a solution of 1% w/v UltraPure agarose (Invitrogen
223 Corporation, Carlsbad, CA, USA) in 20 mL LB. The solution was heated in a
224 microwave until the agarose dissolved completely and the solution was visually
225 homogeneous. The hot agarose solution was placed in a 65 °C water bath for 30 s

226 while air bubbles rose to the surface. To prepare the final plate for growth-curve
227 measurements, we maintained the microplate at 50 °C and pipetted 150 µL LB
228 into the wells in columns 7-12 (these wells lacked magnets) and let the LB warm
229 for >20 min. Using a positive displacement pipette (Eppendorf, Hamburg,
230 Germany), we added 150 µL of agarose prepolymer from a 2.5-mL tip into each
231 well that contained a magnetic stirrer. Antibiotics were added as necessary and
232 the cultures were mixed with magnetic stirrers for ~10 s. The microplate was
233 transferred to a second hotplate set to 37 °C and cooled for 15-20 s. We aliquoted
234 5 µL of each cell suspension using a multichannel pipette into one well with LB
235 and one well with agarose prepolymer to yield an OD ~0.01 and mixed the
236 resulting cultures with magnetic stirrers for ~10 s.

237

238 We then took the microplate off the hotplate, removed the microplate lid, and
239 rapidly applied the magnetic lid to extract the stirrers out of the wells. We
240 removed the magnetic lid and quickly popped any bubbles on the surface of the
241 agarose gel with a sterile pipette tip to ensure that the gel surface was smooth to
242 enable accurate absorbance readings. The lid was again placed on the microplate,
243 which was incubated at room temperature for 5 min while the agarose solidified.
244 The lid was removed and the plate was sealed with a transparent polymer film
245 (Excel Scientific, Victorville, CA, USA). To reduce condensation on the film, we

246 made ~0.25-0.5 cm cuts with a razor blade sterilized with 70% ethanol on
247 opposite sides of each well near its edge. Finally, we placed the microplate into a
248 preheated 37 °C M1000 plate reader (Tecan, Mannedorf, Switzerland) and
249 acquired growth curves at 37 °C by measuring absorbance at 595 nm. The orbital
250 and linear shaking durations were 30 s and 15 s, respectively, and the shaking
251 amplitude was 2 mm. Readings were taken for 16 h at 1-min intervals. The Tecan
252 M1000 plate reader was driven using i-control v. 1.9.17.0 (Tecan), which was
253 used to collect and export data for further analysis.

254

255 **GRABS measurements in variable agarose concentrations**

256 *E. coli* BW25113 was inoculated from a freezer stock into 2 mL LB and grown
257 overnight at 37 °C in a shaking incubator. We measured the absorbance ($\lambda = 600$
258 nm) of a 1:10 dilution in LB of the overnight culture and calculated the volume of
259 culture needed for resuspension in 1 mL of fresh medium for a final absorbance
260 of 2. This volume of cells was spun down at 800 x *g* for 10 min, the supernatant
261 was removed, and the pellet was resuspended in 1 mL LB. The cells were stored
262 at 37 °C until use (within 5 min).

263

264 A stock solution of 5% (w/v) agarose was prepared by dissolving UltraPure
265 agarose into 65 mL LB and placing the solution in a 70 °C water bath. Twenty-

266 milliliter working solutions of 0.25-5% (w/v) agarose were prepared in 50-mL
267 conical tubes by diluting the appropriate volume of 5% (w/v) agarose in
268 preheated LB. These solutions were also placed into the 70 °C water bath. Using
269 a positive displacement pipette, 2 mL of the agarose working solutions were
270 aliquoted into individual preheated glass test tubes and kept at 65 °C in a water
271 bath. Individual tubes were subsequently removed from the 70 °C water bath
272 and allowed to cool in a 37 °C water bath for ~20 s. Ten microliters of the cell
273 suspension were added to each test tube, yielding a final cell density in solution
274 of 0.01 ($\lambda = 600$ nm), and the tube was vigorously shaken to ensure homogenous
275 incorporation of the cells into the agarose solution. Using a positive displacement
276 pipette, 150 μ L of the agarose cell solution were pipetted into a 96-well
277 microplate in replicate ($n \geq 3$). This process was repeated for each agarose
278 concentration. We also monitored growth in liquid LB in order to determine the
279 percent inhibition of each gel compared to liquid. The liquid control was
280 prepared at room temperature with the same cell suspension used for the
281 agarose growth curves. The plate was placed on the bench at room temperature
282 for ~3 min in order to allow the agarose wells to solidify. Growth was monitored
283 with a plate reader.

284

285 **GRABS data analysis**

286 Growth data were collected over 16 h for Keio mutants in both agarose and
287 liquid medium. To reduce the growth curve to a scalar value, we first normalized
288 the growth data in liquid and agarose by subtracting the minimum OD reading
289 (in agarose and liquid) for each mutant. Next, we averaged the 10 min of growth
290 before the 8 h time point, which is approximately when BW25113 cells begin to
291 enter stationary phase in liquid medium (Figure S3A-C). Cells tend to reach
292 saturation at later time points when embedded in agarose (Figure S3A-C), and
293 thus our mechanical phenotype is sensitive to the time point of measurement; $t =$
294 8 h was selected because it provided the largest dynamic range of values (Figure
295 S3A-C). We then determined a percent growth value for each mutant compared
296 to wildtype. The GRABS score is a relative percentage of wild-type OD,
297 calculated as $((OD_{\text{mutant,agarose}}/OD_{\text{WT,agarose}}) - (OD_{\text{mutant,liquid}}/OD_{\text{WT,liquid}}))$. A positive
298 growth value indicates an increase in GRABS score, and a negative growth score
299 indicates a decrease in GRABS score. Note that this GRABS score is a measure of
300 cell mechanics that is complementary, but not identical, to the Young's modulus.
301 For our screen in kanamycin, we normalized all mutant data to an average of
302 several wild-type growth curves in liquid and agarose. In our secondary screen
303 in LB, we used the wild-type control on each plate to normalize the data.

304

305 **Analysis of cell morphology**

306 To estimate the average cell morphology across the Keio collection, images from
307 the National BioResource Project were segmented with a custom MATLAB
308 software package (Ursell et al., 2014). At least 100 cells were included in the
309 calculation of average cell width and length for each Keio mutant.

310

311 **Correlation with chemical-genomics data**

312 To compare GRABS scores against colony growth data from a variety of chemical
313 conditions, we calculated the Pearson correlation coefficient between the GRABS
314 scores for all tested mutants and the S-scores for the equivalent mutants in the
315 chemical condition from Ref. (Nichols et al., 2011). The significance of the
316 correlation for each condition was estimated by comparing the correlation score
317 against the correlation of 1000 random permutations of S-scores.

318

319 **Complementation and deletion assays for GRABS hits and PBP1b mutants**

320 Keio-complementation and wild-type control strains were streaked out from
321 freezer stock onto LB agar plates with appropriate antibiotics to obtain
322 individual colonies. Individual colonies were inoculated into 2 mL LB with
323 appropriate antibiotics and grown overnight at 37 °C. Saturated overnight
324 cultures were diluted 1:100 into 2 mL fresh LB (without antibiotics) and grown to
325 an absorbance of ~0.6 ($\lambda = 600$ nm). Microplates were prepared as described

326 above. For complementation assays, antibiotics were not added to microplate
327 wells so as to not influence the growth of the cells. Five microliters of a 2.5 mM
328 arabinose stock solution were added to the wells containing strains with plasmid
329 pBAD33 c280; the final arabinose gel concentration was 0.08 mM. Strains with
330 wildtype or mutant PBP1b under the control of isopropyl β -D-1-
331 thiogalactopyranoside were not induced; the basal level of expression from the
332 *lac* operon was sufficient for full complementation of the stiffness defect (Figure
333 S4A). Growth curves were compared to curves for the appropriate empty
334 vector/native PBP1b controls to confirm recovery or loss of cell stiffness when the
335 proteins were expressed in *trans*.

336

337 *E. coli* MG1655 mutants ($\Delta mrcB$, $\Delta mrcA$, $\Delta lpoB$, $\Delta lpoA$, $\Delta hscA$, and Δhfq) were
338 streaked out from freezer stocks onto LB agar plates to obtain individual
339 colonies. Individual colonies were inoculated into 2 mL LB and grown overnight
340 at 37 °C. Wild-type and mutant strains were screened for stiffness changes as
341 described above and compared to the corresponding BW25113 mutants.

342

343 **Confirmation of chemical effectors of GRABS measurements**

344 *E. coli* BW25113 and 45 additional Keio strains were grown overnight from
345 freezer stock until saturation, in the appropriate antibiotic. Carbonyl cyanide *m*-

346 chlorophenyl hydrazone (CCCP, Sigma-Aldrich) stock was prepared by
347 dissolving CCCP into dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO,
348 USA). CCCP was diluted into 1 mL LB to yield a 64 µg/mL working solution. The
349 GRABS plate and cells were prepared as described above. During preparation of
350 the GRABS plate, 5 µL CCCP were added to each well. The final concentrations
351 of CCCP and DMSO in the plate were 2 µg/mL and ~0.1%, respectively.
352 Appropriate DMSO-only controls were performed to confirm that DMSO did not
353 affect the GRABS score. The percent growth values were determined as
354 described, using the BW25113 (DMSO+) and (CCCP+) wells to normalize data
355 from the mutants.

356

357 **Microscopy-based stiffness measurements**

358 Single-cell measurements of encapsulated cell growth were performed in 1-4%
359 (w/v) agarose as described previously (Tuson et al., 2012). Briefly, bacteria were
360 grown in liquid LB without antibiotics to an absorbance ($\lambda = 600$ nm) of ~0.6. Cells
361 were diluted 1:100 and spotted onto 2% agarose pads. Elongation was monitored
362 on a Nikon Eclipse Ti inverted microscope (Nikon, Tokyo, Japan) equipped with
363 a heated stage (Okolab, Pozzuoli, Italy) and objective heater (Bioprotechs, Butler,
364 PA, USA) at 37 °C. Images were collected over a 30-min period at 1-min intervals
365 using a CoolSNAP HQ2 camera (Photometrics, Munich, Germany). Cell length

366 was measured for each mutant and wild-type strain using MicrobeTracker
367 (Sliusarenko et al., 2011). Length measurements were halted after cells divided.
368 We calculated the fractional elongation over time for each mutant, averaged over
369 all single cells (Tuson et al., 2012).

370

371 **Microfluidic-based stiffness measurements**

372 Keio mutants and wild-type strains were transformed with a plasmid (pDB192)
373 containing *sulA* under an isopropyl β -D-1-thiogalactopyranoside-inducible
374 promoter. The strains were grown overnight in 2 mL LB containing 30 μ g/mL
375 kanamycin and 50 μ g/mL ampicillin. We fabricated and applied a microfluidic
376 device to the determination of cellular bending rigidity and Young's modulus as
377 described previously (Amir et al., 2014). As an alternative means of causing cells
378 to filament, we applied 1 μ g/mL aztreonam (MP Biomedicals, CA, USA).

379 Deflection of cells under fluid flow was monitored on a Zeiss Axiovert 100
380 microscope (Zeiss, Oberkochen, Germany) equipped with a 60X oil objective.

381 Images were collected with an Andor iXon 3 EMCCD (Andor, Belfast, UK) using
382 μ Manager v. 1.4.16 (Edelstein et al., 2010). Deflection of the cells was determined
383 using a custom Igor Pro (WaveMetrics Inc.) image analysis algorithm.

384

385 To account for changes in the diameter of mutant cells compared to wild-type
386 cells after filamentation, we collected static images on a Nikon Eclipse Ti
387 inverted microscope equipped with a 60X oil objective (Nikon) using a
388 CoolSNAP HQ2 camera (Photometrics). Cell width was measured using
389 MicrobeTracker (Sliusarenko et al., 2011). These measurements were used to
390 calculate the Young's modulus from the flexural rigidity, in which the moment of
391 inertia (I) of a cross-section is dependent on cell radius (r) and thickness of the
392 cell wall (h) according to $I = \pi r^3 h$.

393

394 **Cell death in 1% agarose and liquid**

395 The GRABS assay for Keio mutants and wild-type strains was carried out as
396 described above. One hundred and fifty microliters of liquid LB and agarose
397 (prior to gelling) were pipetted out of the 96-well plate and transferred to an 8-
398 well LAB-TEK II chambered coverglass #1.5 (Nunc, NY, USA). The agarose was
399 allowed to solidify at room temperature. LAB-TEK II chambers were placed into
400 a 37 °C incubator with shaking for 8 h, at which point the GRABS score was
401 determined. After 8 h, cells were removed from the 37 °C incubator and labeled
402 via the LIVE/DEAD BacLight Viability Kit (L7007, Invitrogen) at room
403 temperature. For staining of cells grown in liquid, cells were diluted 1:20 in fresh
404 LB and stained in the dark for 20 min according to the manufacturer's guidelines.

405 For staining of cells grown in agarose, 25 μ L of a stock solution (100 μ L
406 component A (1.67 mM SYTO 9, 1.67 mM Propidium iodide) + 1.5 μ L component
407 B (1.67 mM SYTO 9, 18.3 mM Propidium iodide)) were pipetted onto the agarose
408 surface and allowed to diffuse through the gel in the dark for 30 min. Cells
409 were imaged with epifluorescence using a Nikon Ti inverted microscope
410 equipped with a CoolSNAP HQ2 camera (Photometrics) and a 100X oil objective
411 (Nikon).

412

413 **Purification of sacculi and ultra performance liquid chromatography (UPLC)**
414 **of peptidoglycan composition**

415 Overnight cultures of *E. coli* BW25113 or Keio strains were diluted 1:100 in LB
416 and grown at 37 °C to an OD₆₀₀ of 0.7. The cultures were then harvested by
417 centrifugation at 5,000 \times g for 10 min at room temperature and resuspended in 3
418 mL LB. Cell suspensions were lysed by boiling in sodium dodecyl sulfate, and
419 insoluble material was collected by several rounds of ultracentrifugation at
420 400,000 \times g for 20 min at room temperature. Samples were prepared for UPLC as
421 previously described (Brown et al., 2012) and injected onto a Waters H Class
422 UPLC system equipped with a BEH C18 1.7- μ m column (Waters, MA, USA),
423 using elution conditions previously described (Desmarais et al., 2014). Peaks
424 were quantified and identified as particular muropeptide species using the

425 software package Chromanalysis (Desmarais et al., 2015), from which the
426 crosslinking density and strand length were calculated (Ottolenghi et al., 1993;
427 Pisabarro et al., 1985).

428

429 **Shape of agarose-embedded cells**

430 The GRABS assay for Keio mutants and wild-type strains was carried out as
431 previously described. One hundred and fifty milliliters of agarose (prior to
432 gelling) were pipetted out of the 96-well plate and transferred to an 8-well LAB-
433 TEK II chambered coverglass #1.5 w/cover (Nunc, NY, USA). The agarose was
434 allowed to solidify at room temperature. LAB-TEK II chambers were placed into
435 a 37 °C incubator with shaking for 8 h (at which point the GRABS score is
436 typically determined). After 8 h, cells were removed from the incubator and
437 labeled with FM 4-64 FX (Invitrogen). For staining, 25 μL of a 100 g/L stock
438 were pipetted onto the surface of the agarose and allowed to diffuse through the
439 gel, in the dark, for 30 min. Cells were imaged using phase contrast and
440 epifluorescence microscopy.

441

442 **Cell density versus OD measured by plate reader**

443 A saturated overnight culture of *E. coli* BW25113 was diluted 1:100 into 60 mL of
444 fresh LB and grown in a 37 °C incubator with shaking until an absorbance of 3.0

445 ($\lambda = 600$ nm). We calculated the volume of the culture needed for resuspension in
446 200 μ L of fresh LB medium for a final absorbance of 248 OD. This volume of cells
447 was spun down at $800 \times g$ for 10 min, the supernatant was removed, and the
448 pellet was resuspended in fresh LB media. A 2-fold dilution series was made
449 from 240 OD to 0.007 OD. Five microliters of diluted culture were inoculated
450 into agarose for a final cell density in the plate of 8 OD-0.0004 OD. The OD ($\lambda =$
451 595 nm) was measured immediately using a Tecan M200 PRO plate reader.

452

453 **Measurement of SOS using a promoter-fusion assay**

454 To measure SOS induction we used the plasmids pUA66-*sulA* promoter-GFP
455 (p*SulA*-GFP) and the empty vector control pUA66-GFP (pUA66) transformed in
456 the Keio parent strain *E.coli* BW25113 and the Keio strains ($\Delta mrcB$, $\Delta lpoB$, $\Delta hscA$,
457 Δhfq , $\Delta iscA$, $\Delta recA$). Three biological replicates of wildtype cells and Keio strains
458 containing p*SulA*-GFP and pUA66 were inoculated from a plate of overnight
459 cultures in LB and grown at 37 °C in an incubator with shaking. The GRABS
460 assay was carried out as described above. As a positive control to test the effects
461 of inducing the SOS response, norfloxacin was added at three times the
462 minimum inhibitory concentration (30 ng/mL) to wild-type cells grown in liquid
463 and embedded in agarose. OD was measured at $\lambda = 595$ nm and GFP

464 fluorescence was measured with excitation at 485 nm and emission at 515 nm
465 using a Tecan M200 PRO plate reader at 10 min intervals for 8 h.
466
467 Analysis of SOS induction was performed by first normalizing the data to
468 fluorescence intensity per cell for p*SulA*-GFP and pUA66 at each time point (t)
469 using the ratio (fluorescence intensity(t)/optical density(t)). We corrected for
470 basal GFP expression by subtracting normalized fluorescence values of pUA66
471 from p*SulA*-GFP at each time point: $(pSulA-GFP_{normalized}(t) - pUA66_{normalized}(t))$. 3
472 biological replicates were averaged at each time point. We subtracted average
473 fluorescence values at $t = 0$ from each subsequent time point to monitor changes
474 in SOS induction for 1% agarose and liquid.

475 **Supplemental References**

476

477 Amir, A., Babaeipour, F., McIntosh, D.B., Nelson, D.R., and Jun, S. (2014).

478 Bending forces plastically deform growing bacterial cell walls. *Proceedings of the*

479 *National Academy of Sciences of the United States of America* 111, 5778-5783.

480 Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko,

481 K.A., Tomita, M., Wanner, B.L., and Mori, H. (2006). Construction of *Escherichia*

482 *coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol Syst*

483 *Biol* 2, 2006 0008.

484 Brown, P.J., de Pedro, M.A., Kysela, D.T., Van der Henst, C., Kim, J., De Bolle, X.,

485 Fuqua, C., and Brun, Y.V. (2012). Polar growth in the Alphaproteobacterial order

486 Rhizobiales. *Proc Natl Acad Sci USA* 109, 1697-1701.

487 Desmarais, S.M., Cava, F., de Pedro, M.A., and Huang, K.C. (2014). Isolation and

488 preparation of bacterial cell walls for compositional analysis by ultra

489 performance liquid chromatography. *J Vis Exp*, e51183.

490 Desmarais, S.M., Tropini, C., Miguel, A., Cava, F., Monds, R.D., de Pedro, M.A.,

491 and Huang, K.C. (2015). High-throughput, Highly Sensitive Analyses of Bacterial

492 Morphogenesis Using Ultra Performance Liquid Chromatography. *The Journal*

493 *of biological chemistry* 290, 31090-31100.

494 Edelstein, A., Amodaj, N., Hoover, K., Vale, R., and Stuurman, N. (2010).
495 Computer control of microscopes using microManager. *Current protocols in*
496 *molecular biology* / edited by Frederick M Ausubel [et al] *Chapter 14, Unit14* 20.

497 Nichols, R.J., Sen, S., Choo, Y.J., Beltrao, P., Zietek, M., Chaba, R., Lee, S.,
498 Kazmierczak, K.M., Lee, K.J., Wong, A., *et al.* (2011). Phenotypic landscape of a
499 bacterial cell. *Cell* *144*, 143-156.

500 Ottolenghi, A.C., Caparros, M., and de Pedro, M.A. (1993). Peptidoglycan
501 tripeptide content and cross-linking are altered in *Enterobacter cloacae* induced
502 to produce AmpC beta-lactamase by glycine and D-amino acids. *J Bacteriol* *175*,
503 1537-1542.

504 Philippe, N., Alcaraz, J.P., Coursange, E., Geiselman, J., and Schneider, D.
505 (2004). Improvement of pCVD442, a suicide plasmid for gene allele exchange in
506 bacteria. *Plasmid* *51*, 246-255.

507 Pisabarro, A.G., de Pedro, M.A., and Vazquez, D. (1985). Structural modifications
508 in the peptidoglycan of *Escherichia coli* associated with changes in the state of
509 growth of the culture. *J Bacteriol* *161*, 238-242.

510 Sliusarenko, O., Heinritz, J., Emonet, T., and Jacobs-Wagner, C. (2011). High-
511 throughput, subpixel precision analysis of bacterial morphogenesis and
512 intracellular spatio-temporal dynamics. *Mol Microbiol* 80, 612-627.

513 Tuson, H.H., Auer, G.K., Renner, L.D., Hasebe, M., Tropini, C., Salick, M., Crone,
514 W.C., Gopinathan, A., Huang, K.C., and Weibel, D.B. (2012). Measuring the
515 stiffness of bacterial cells from growth rates in hydrogels of tunable elasticity.
516 *Mol Microbiol* 84, 874-891.

517 Ursell, T.S., Nguyen, J., Monds, R.D., Colavin, A., Billings, G., Ouzounov, N.,
518 Gitai, Z., Shaevitz, J.W., and Huang, K.C. (2014). Rod-like bacterial shape is
519 maintained by feedback between cell curvature and cytoskeletal localization.
520 *Proceedings of the National Academy of Sciences of the United States of America*
521 111, E1025-1034.

522